Correction: Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening Free

In this article (Clin Cancer Res 2016;22:243–9), which was published in the January 1, 2016, issue of Clinical Cancer Research (1), the grant support is listed incorrectly. It should read as follows: “The coordination of the ERSPC trial has been financially supported in part by the 6th Framework programme of the EU; European Commission Europe against Cancer programme; and an unconditional grant from Beckmann-Coulter-Hybritech. The Finnish center has been financially supported by grants from the Academy of Finland (grant #260 931); Cancer Society of Finland; Pirkanmaa Hospital District Competitive Research Funding, and Nordic Cancer Union; the Dutch Center by the Dutch Cancer Society, and the Netherlands Organization for Health Research and Development (ZonMW); Sweden by Abbott Pharmaceuticals; Af Jochnick Foundation; Catarina and Sven Hagstroms Family Foundation, Gunvor and Ivan Svensson Foundation; Johanniterorden; King Gustav V Jubilée Clinic Cancer Research Foundation; Sahlgrenska University Hospital; Schering Plough; Swedish Cancer Society; and Wallac Oy; Belgium by Flemish Ministry of Welfare, Public Health and Family; Province and City of Antwerp; Public Centre for Social Welfare Antwerp; Italy by Italian League for the Fight against Cancer (LILT); Italian Association for Cancer Research (AIRC); and National Research Council (CNR), Tuscany Region; Switzerland by The Horten Foundation; Aargau Cancer League; Swiss Cancer League; Health Department of Canton Aargau; Prostate Cancer Research Foundation; Baugarten Foundation; and the Messerli Foundation; and Spain by The Spanish ‘Fondo de Investigacíon Sanitaria.’ This study was also partly funded by the NIH/NCI Cancer Center Support Grant P30 CA008748.” The authors regret this error.